HOXB9 and lung carcinoma: Interestingly, in two independent clinicogenomics studies (GSE31210 and GSE8894), HOXB9 expression was most significantly altered in patients with high-grade tumors (GSE31210) and in recurrent lung cancer (GSE8894), respectively.